Protein aggregation remains a major area of focus in the production of monoclonal
antibodies. Improving the intrinsic properties of antibodies can improve manufacturability …

Monoclonal antibodies are attractive therapeutics for treating a wide range of human
disorders due to their exquisite binding specificity and high binding affinity. However, a …

Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …

The ability of antibodies to bind to target molecules with high affinity and specificity has led
to their widespread use in diagnostic and therapeutic applications. Nevertheless, a limitation …

Therapeutic proteins such as antibodies constitute the most rapidly growing class of
pharmaceuticals for use in diverse clinical settings including cancer, chronic inflammatory …

Protein aggregation can hinder the development, safety and efficacy of therapeutic antibody-
based drugs. Developing a predictive model that evaluates aggregation behaviors during …

Aggregation of a biotherapeutic is of significant concern and judicious process and
formulation development is required to minimize aggregate levels in the final product …

Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

Aggregation is a common problem affecting biopharmaceutical development that can have a
significant effect on the quality of the product, as well as the safety to patients, particularly …

Determining the aggregation propensity of protein-based biotherapeutics is an important
step in the drug development process. Typically, a great deal of data collected over a large …